CClinicalTrials.gg
CompletedNCT05720806Updated May 13, 2026

Weight Bearing Status Post-hip Arthroscopy

An interventional study of Weight Bearing as tolerated (WBAT) immediately following surgery. and Flat foot weight bearing (FFWB) immediately following surgery in Hip Impingement Syndrome and Acetabular Labral Tear, sponsored by University of Pittsburgh. Completed at 1 site in United States. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
12 Years to 65 Years
Sex
All
01

Study summary

This study is being proposed to examine weight bearing precautions following hip arthroscopic labral repair, femoroplasty, and capsular closure. Standard post operative protocols limit weight bearing for 2-6 weeks depending on individual surgeons. Cadaveric studies demonstrate that minimal force during weight bearing is distributed through labrum. Therefore, progressing weight bearing earlier in these patients post operatively may help progress faster and improve outcomes. Data collected will include demographic information, radiological data, operative procedures and PRO data.

Read the detailed description

The study will be conducted at UPMC St. Margaret's Hip Preservation Program. Consented patients who undergo acetabular labral repair and femoroplasty will be included in randomization of weight-bearing status. Two separate protocols will be created to indicate weight bearing status, either WBAT immediately post-op or FFWB immediately post-op, to distribute to rehabilitation staff to ensure compliance. Immediately after the surgical procedure, the surgeon will be blinded and a randomized pamphlet with post-operative instructions with weight bearing education will be given to PACU nursing staff to educate patients and fit crutches.

02

Conditions studied

  • Hip Impingement Syndrome
  • Acetabular Labral Tear
03

In context

Lead sponsor

University of Pittsburgh is the lead sponsor of 1,385 studies on the registry; 167 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age>= 12 years
  • Diagnoses: femoroacetabular impingement and hip labral tears.
  • Surgical procedures performed: Hip arthroscopy with femoroplasty and labral repair.
  • Surgery completed at UPMC Children's or UPMC St. Margaret's Hospital
  • unilateral and bilateral hip patients

Exclusion criteria

Exclusion Criteria:

  • MSK tumor-related FAI or dysplasia
  • generalized hypermobility
  • revision surgeries
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Weight bearing as tolerated (WBAT) immediately following surgery.

    Subjects will be able to self-select weight bearing based on pain and confidence in surgical hip.

    Other: Weight Bearing as tolerated (WBAT) immediately following surgery.

  • Active comparator
    Flat foot weight bearing (FFWB) for 2 weeks after surgery.

    Subjects will be limited to FFWB, approx 20lbs through the surgical hip.

    Other: Flat foot weight bearing (FFWB) immediately following surgery

Interventions

  • OtherWeight Bearing as tolerated (WBAT) immediately following surgery.

    Subject will be provided standard of care physical therapy following surgical intervention, except will be able to self-select weight bearing based on pain and confidence.

  • OtherFlat foot weight bearing (FFWB) immediately following surgery

    Subject will be provided standard of care physcial therapy following surgical intervention except

06

What researchers measure

Primary outcomes

  1. International Hip Outcome Tool 12 (iHot-12)

    Scoring ranges from 0-100 * each question is rated from 0-100 and final score is the mean of all questions answered by subject * higher scoring indicating higher quality of life due to hip function

    Time frame: up to 6 months post-operative

  2. Hip and Groin Outcome Score (HAGOS)

    This outcome includes 6 subscales, these are scored independently, and no aggregate scoring is calculated as each section assesses different dimensions separately. Subscales (raw scores for each subscale converted to a 0-100 scale with higher score indicating higher level of function): * Pain * Symptoms * Activities of Daily Life * Function in Sport and recreation * Participation in Physical Activities * hip and groin-related quality of life

    Time frame: up to 6 months post-operative

  3. Hip Outcome Score (HOS) ADL

    Outcome assessing function with activities of daily living. Higher score is given for higher level of function and lower score indicating reduced function. 0-68 aggregate scoring converted to 0-100 scale.

    Time frame: up to 6 months post-operative

  4. Hip Outcome Score (HOS) Sport

    Outcome assessing function/difficulty completing dynamic activities associated with sports participation. Higher score is given for higher level of function and lower score indicating reduced function. 0-36 aggregate scoring converted to 0-100 scale.

    Time frame: up to 6 months post-operative

  5. Tampa Scale for Kinesiophobia-11

    Outcome measure assessing fear of pain with movement. Scores range from 11 to 44. Higher scores indicate greater fear of movement

    Time frame: up to 6 months post-operative

Secondary outcomes

  1. Isometric strength measures hip add, abd, ER, and extension

    Strength measures will be taken isometrically at post-operative follow ups.

    Time frame: 6-week, 3 months, and 6-month post-operative

  2. Diagnostic ultrasound assessment of bilateral anterior hip capsule thickness

    Physician while blinded will perform ultrasound evaluation of the hip capsule to ensure healing. Ultrasound will measure the following: 1.Assess the bilateral hip anterior capsule in all patients, assessing for internal consistency or changes in capsular thickness from side to side. Normal hip capsular thickness has been reported as 7-8 mm, dysplastic hips range 3.2 +/- 0.5 mm, and femoroacetabular impingement subjects 4.7 +/- 0.6 mm.

    Time frame: 3 months post-operative

  3. Diagnostic ultrasound assessment of incision widening

    Physician while blinded will perform ultrasound evaluation of the hip capsule to ensure healing. 1\. Evaluation of capsular incision widening, cyst, attenuation and thinning from established norms. Normal hip capsular thickness has been reported as 7-8 mm, dysplastic hips range 3.2 +/- 0.5 mm, and femoroacetabular impingement subjects 4.7 +/- 0.6 mm

    Time frame: 3 months post-operative

  4. Diagnostic ultrasound for focal echogenic adhesions

    Physician while blinded will perform ultrasound evaluation of the hip capsule to ensure healing. 1\. Evaluate for focal echogenic adhesions or dyskinetic motion between capsule and overlying iliopsoas complex with activation of hip flexion.

    Time frame: 3 months post-operative

07

Study locations

1 site
  • UPMC Hip Preservation Program
    Pittsburgh, Pennsylvania 15238, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05720806
Lead sponsor
University of Pittsburgh
Responsible party
Craig Mauro (Clinical Associate Professor, University of Pittsburgh) — Principal investigator
First posted
Feb 9, 2023
Start date
May 1, 2023
Primary completion
Dec 5, 2025
Completion
Mar 22, 2026
Last update
May 13, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion